Starling Oncology, Inc. (STLN) Stock Price & Analysis

Starling Oncology, Inc. (STLN) rose 6.58% to USD 6.32 as of September 9, 2026 at 00:17 UTC, according to Nexqual real-time market data.

STLN last closed at USD 6.32; the session ranged USD 5.85–6.48 on volume of 1,774,593 shares. Market capitalization is —, with a 52-week range of USD 2.32–7.05 (NCM). Source: Nexqual, September 9, 2026 at 00:17 UTC.

Key Statistics (as of September 9, 2026 at 00:17 UTC)

Technical Analysis (STLN)

Nexqual's technical model rates STLN "BUY" based on 4 bullish and 2 bearish signals across 126 daily candles, as of September 9, 2026 at 00:17 UTC.

From Starling Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• Market Overview Our business is focused on caring for adult and senior populations with medical oncology and related care needs, including members of MA plans run by private insurance companies on behalf of the Centers for Medicare and Medicaid Services, or CMS, as well as traditional FFS Medicare, Medicaid, other government healthcare programs and commercial insurance populations.
• Some of the biggest and most respected names in healthcare contract with the TOI PCs to provide oncology care to their members, including Anthem, CareMore Health, Heritage Provider Network and Optum Care.
• In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission ("FTC") Act, that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of the TOI PCs.
• We generate these referrals based on the reputation of our doctors and our platform within the communities we serve, as well as our active and direct referrer education efforts.

Partnerships

• In the wake of the Executive Orders and related executive initiatives, a number of pharmaceutical manufacturers have announced new or expanded direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding discounted pricing for drugs, including prices for Medicaid drugs and newly launched products.
• We have entered into a management services agreement with each of the TOI PCs, which are entirely physician owned.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 00:17 UTC. This page is informational and not investment advice.